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Abstract. Breast cancer, the most common spontaneous
malignancy diagnosed in women, is a classical model of
hormone dependency as it is associated with prolonged exposure to female hormones. Different cytoplasmic proteins are
important in the transformation of a normal cell to an invasive
tumor cell, and these include vimentin and Notch. To investigate the importance of these two genes and proteins in breast
carcinogenesis, we used an in vitro breast cancer model system,
in which an immortalized human breast epithelial cell line,
MCF‑10F, was malignantly transformed by exposure to low
doses of high linear energy transfer α particle (150 keV/µm)
radiation and subsequent growth in the presence or absence of
17β‑estradiol. This model consisted of human breast epithelial
cells in different stages of transformation: i) a parental cell line
(MCF‑10F), ii) an Estrogen cell line (MCF‑l0F continuously
grown with estradiol at 10‑8), iii) a malignant and non-tumorigenic cell line (Alpha3), iv) a malignant and tumorigenic cell
line (Alpha5) and v) a Tumor2 cell line derived from a xenograft
of the Alpha5 cell line injected into nude mice. Vimentin and
Notch showed greater expression in the Alpha5 and Tumor2
cell lines compared with that in the non‑tumorigenic cell lines,
MCF‑10F, Estrogen and Alpha3. In the present study, positive
staining for vimentin was found in 21% of cases. Vimentin and
Notch protein expression was negative in noninvasive ductal
carcinoma biopsies from breast cancer patients. However,
positive cell expression was observed in invasive ductal carcinoma biopsies. These biomarkers can be considered important
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indicators of breast cancer progression and can be added to the
diagnostic panel when overall survival is a primary end‑point.
Introduction
Breast cancer, the most common spontaneous malignancy
diagnosed in women, is a classical model of hormone dependency. There is evidence that breast cancer risk is associated
with prolonged exposure to female hormones, as the onset of
menarche, late menopause and hormone replacement therapy
are associated with greater cancer incidence (1). The progression of breast cancer follows a complex multi‑step process that
depends on various exogenous (diet and breast irradiation) and
endogenous (age, hormonal imbalances, proliferative lesions
and family history of breast cancer) factors (2‑4). Breast cancer
is a complex disease in which numerous genetic aberrations
occur. Cellular and molecular changes that occur during the
development of cancer can be mediated by a range of endogenous and environmental stimuli. On the basis of the currently
accepted view of breast cancer as a multi‑step process, it is
possible that specific abnormalities may be an essential part of
the transformation of a normal cell to an invasive tumor cell.
Different cytoplasmic proteins are key in the transformation of a normal cell to an invasive tumor cell and
among these, vimentin is particularly important. It is one of
the cytoplasmic intermediate filament proteins, which are
the major components of the cytoskeleton normally found
in embryonic or mesenchymal stem cells (5,6). However,
vimentin is frequently expressed in neoplastic cells with
metastatic properties, including breast cancer cells (7,8). It is
a 57‑kDa intermediate filament protein, which forms a part of
the cytoskeleton. Expression of vimentin and cytokeratins has
also been described in breast carcinomas. Hendrix et al (9)
demonstrated that the co‑expression of vimentin and keratin
intermediate filaments in human breast cancer cells results in
phenotypic inter‑conversion and increased invasive behavior.
Another important gene, Notch, is also pivotal in this
context. This gene is expressed in a variety of tissues, indicating that it is involved in multiple signaling pathways (10‑14).
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It is either overexpressed or rearranged in human tumors, such
as is the case with the 280‑ to 330‑kDa Notch protein (14).
The LIN‑12/Notch family of transmembrane receptors is
believed to be central to development by regulating cell fate
decisions (10-13). Notch signals are involved in the development and maintenance of normal tissues that are recapitulated
in different forms of cancer (14,15). Notch can either promote
or limit tumor growth, depending on the tumor type, through
differentiation, cellular metabolism, cell cycle progression,
angiogenesis and possibly self‑renewal and immune function (16,17,19,20). The Notch signaling pathway is critical
in cell fate decisions, tissue patterning and morphogenesis,
and is hence regarded as a developmental pathway. However,
problems with this pathway can contribute to cellular transformation and tumorigenesis.
The expression of Notch receptors and their downstream target genes is upregulated in primary human
melanomas (15,16), and the expression of constitutively active
Notch1 promotes melanoma progression (15,17). These oncogenic effects correlate with the activation of Wnt signaling
in melanoma cells (15), which promotes the expression of
adhesion molecules such as N‑cadherin (17) through the transcription factor TCF/LEF (15). Notch has also been implicated
in the pathogenesis of other solid tumors, such as medulloblastoma (18,19) and ovarian cancer (20), and the number of known
neoplasms involving some alteration in Notch signaling is
increasing. The aim of the present study was to assess whether
vimentin and Notch gene and protein expression are altered
in breast cancer progression. The importance of vimentin
expression was analyzed by identifying cases of breast cancer
with poor prognosis and comparing vimentin and Notch as
biomarkers required for prognosis in breast cancer patients.
Materials and methods
Cell lines. MCF‑10F cells were grown in DMEM/F‑12 (1:1)
medium supplemented with antibiotics [100 U/mI penicillin,
100 µg/ml streptomycin and 2.5 µg/ml amphotericin B
(all from Life Technologies, Grand Island, NY, USA)] and
10 µg/m of 5% equine serum (Biofluids, Rockville, MD, USA),
0.5 µg/ml hydrocortisone (Sigma‑Aldrich, St. Louis, MO,
USA) and 0.02 µg/ml epidermal growth factor (Collaborative
Research, Bedford, MA, USA) (21). An in vitro experimental
breast cancer model (Alpha model) (22), developed by
exposing the immortalized human breast epithelial MCF‑10F
cell line to low doses of high linear energy transfer α particle
radiation (150 keV/µm) and subsequent growth in the presence
or absence of 17β‑estradiol, was used in this study. This model
consisted of human breast epithelial cells in different stages of
transformation: i) a control cell line (MCF‑10F), ii) an Estrogen
cell line [(MCF‑l0F continually treated with estradiol at
10‑8 M (Sigma‑Aldrich)], iii) a malignant but non-tumorigenic
cell line (Alpha3), iv) a malignant and tumorigenic cell line
(Alpha5) and v) a Tumor2 cell line derived from cells originating from a tumor after injection of the Alpha5 cell line into
nude mice. A total of 21 female CB17 SCID mice (Taconic,
Germatown, NY, USA) and nude mice (Harlam Sprague
Dawley, Indianapolis, IN, USA) (age, 1 year) were used in
these studies. Each animal was injected subcutaneously at two
different sites with 8x106 cells in 0.2 ml saline in the fat pad

of the right and left side of the abdominal mammary gland.
The study was approved by the ethics committee of Columbia
University Medical Center (New York, NY, USA)
Pathological analysis. Formalin‑fixed, paraffin‑embedded,
noninvasive and invasive ductal and lobular carcinomas were
obtained from the archives of the Pathology Department of
Dr Gustavo Fricke Hospital, Viña del Mar, Valparaíso, Chile.
Patients had undergone surgery (total mastectomy with axillary
lymph node dissection) between 1997 and 2001. The median
patient age at surgery was 56 years (range, 25‑92 years). The
primary pathological diagnosis was confirmed by hematoxylin
and eosin staining. All operative and pathological reports
were reviewed to confirm disease stage. Sections of 2 µm
were cut and mounted onto polylysine‑coated slides, and
stained for vimentin and Notch protein expression. The study
was approved by the ethics committee of Dr. Gustavo Fricke
Hospital of Viña del Mar (Valparaiso, Chile).
Immunoperoxidase staining. Protein expression was
evaluated as previously described (22‑24). Exponentially
growing cell lines were plated on a glass chamber slide
(Nunc Inc., Naperville, IL, USA) at a density of 1x10 4
cells/ml of medium and allowed to grow for 2‑3 days until
they reached 70% confluence (21). The cells were fixed with
buffered paraformaldehyde at room temperature, incubated
with 1% H 2O2 in methanol to block endogenous peroxidase
and washed twice with buffer solution. Cell cultures were
subsequently covered with normal horse serum for 30 min
at RT and incubated with anti‑rabbit monoclonal antibody
(vimentin: C‑20, sc 7557 and Notch 4: C‑19, sc 8644) (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a 1:500
dilution at 4˚C overnight, and then incubated for 45 min with
diluted biotinylated secondary antibody solution (Vector
Laboratories, Burlingame, CA, USA) and Vectastin Elite
ABC Reagent (Vector Laboratories). The experiments were
repeated three times in cells with identical passages in vitro.
The number of immune‑reactive cells (50 cells/field) was
counted in several randomly selected microscopy fields
(x400) per sample using an optical microscope (CX31;
Olympus Corporation, Tokyo, Japan). Ten fields were counted
for each cell line.
Inmunofluorescent staining. Protein expression was evaluated by immunofluorescent staining and confocal microscopy
as previously described (22,23). Cells were viewed on Zeis
Axiovert 100 TV microscope (Carl Zeiss, Thornwood, NY,
USA) using a 40X 11.3 NA objective lens equipped with a
laser scanning confocal attachment (LSM 410, Carl Zeiss).
A semi-quantitative estimation of the area and the intensity
of the staining of the cells present in the culture dishes
were performed based on the relative staining of the protein
expressed by the controls and transformed cells.
Fluorescent‑labeled probe preparation for micro‑
array analysis. The poly(A) m RNA from normal,
radiation‑ and estrogen‑treated breast cell lines was isolated
using a QIA‑direct‑mRNA isolation kit (Qiagen, Inc.,
Valencia, CA, USA). Fluorescent‑labeled cDNA was prepared
from 1 µg of each of these poly(A) mRNA samples by
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Figure 1. Bars represent the average and standard error of vimentin protein expression by (A) peroxidase and (B) immunofluorescent techniques of the
MCF‑10F, Estrogen, Alpha3, Alpha5 and Tumor2 cell lines. The primary antibodies used were mouse monoclonal antibodies (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA). Fold change of (C) vimentin and (D) Notch gene expression. Gene expression from scatter plots of the following pairwise comparative
studies of cell lines: MCF‑10F/E (1), MCF‑10F/Alpha3 (2), E/Alpha5 (3), Alpha3/Alpha5 (4), Alpha 3/Tumor2 (5) and Alpha5/Tumor2 (6).

using oligo dT‑primed polymerization and a Superscript II
reverse transcriptase kit (Life Technologies) in the presence
of either Cy3‑ or Cy5‑labeled dCTP, following the usual
procedure (http://cmgm.stanford.edu/pbrown/protocols/). The
appropriate Cy3‑ and Cy5‑labeled probes were pooled and
hybridized to microarray glass coverslips for 16 h at 65˚C and
then washed with high stringency for analysis.
Affymetrix HG‑U133A Plus 2.0 GeneChip microarray gene
expression analysis. The breast cancer model (Alpha model)
containing i) MCF‑10F, ii) Estrogen, (iii) Alpha3, iv) Alpha5
and v) Tumor2 cell lines was analyzed for gene expression using Affymetrix U133A oligonucleotide microarray
(Affymetrix, Santa Clara, CA, USA), which contains 14,500
genes. Arrays were quantitatively analyzed for gene expression using the Affymetrix GeneChip Operating Software, with
dual global scaling option in a Genes@Work software platform of discovery algorithm, Structural Pattern Localization
Analysis by Sequential Histograms, and a false discovery rate
of 0.05 (25,26).
Results
Phenotypic and molecular analysis of vimentin expression
in breast cancer progression model. The established breast
cancer model (22) has been shown to exhibit important phenotypic characteristics of breast carcinogenesis. The normal
cell line, MCF‑10F, did not exhibit any of the features that
characterize malignant cells, such as anchorage‑independent
growth in soft agar, invasion and tumor growth in nude
mice (22,24). The Alpha3 cell line formed colonies in soft
agar and had invasive capabilities, but failed to form tumors in
the immuno‑suppressed mice. However, the Alpha5 cell line
induced mammary gland tumors in the animals and metastasis

in the liver, lung and kidneys after injection. This cell line gave
rise to the Tumor2 cell line after removal of the mammary
tumor, digestion in in vitro conditions and culture for many
passages.
The analysis of immunoperoxidase (Fig. 1A) and immunofluorescence (Fig. 1B) data obtained in relation to the relative
vimentin expression in MCF‑10F, Estrogen, Alpha3, Alpha5
and Tumor2 cell lines indicated that such expression was significantly greater (P<0.05) in the Tumor2, Alpha3 and Alpha5 cell
lines, when compared with the MCF‑10F and Estrogen cell
lines. Genes that were identified to be differentially expressed
between cell lines of this model were also studied. Histogram
plots of the differential expression of vimentin and Notch genes
in these cell lines were detected by gene chip array. Results
of pairwise comparisons of cell lines examined for vimentin
protein expression were analyzed with the following pairs of cell
lines: MCF‑10F/Estrogen, MCF‑10F/Alpha3, Estrogen/Alpha5,
Alpha3/Alpha5, Alpha5/Tumor2 and Alpha 3/Tumor2 (Fig. 1C).
Results of the pairwise comparisons did not reveal any alteration in vimentin gene expression between the MCF‑10F and
Estrogen cell lines, while there was an almost nine‑ and five‑fold
alteration in the MCF‑10F/Alpha3 and Estrogen/Alpha5 combinations, respectively. There were six‑ and four‑ fold changes in
gene expression between the Alpha5 and Tumor2 cell lines, and
Alpha3 and Tumor2 cell lines, respectively.
Results of pairwise comparisons of cell lines examined
for Notch gene expression are shown in Fig. 1D. Results of
the same pairs of cell lines were analyzed, revealing no
alteration in Notch gene expression between the MCF‑10F
and Estrogen cell lines, Estrogen and Alpha5 cell lines, and
Alpha3 and Alpha5 cell lines. By contrast, there was an
almost ten‑ and fourteen‑fold alteration in the Alpha5/Tumor2
and Alpha3/Tumor2 combinations, respectively, with higher
expression in Alpha3 and Alpha5 than in Tumor2.
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Figure 2. Representative images of vimentin protein expression stained by (A‑C) immunoperoxidase and (D‑F) immunofluorescent techniques in a breast cancer
cell model. Biopsy specimens containing (G‑I) ducts and lobules, and (J‑L) invasive carcinoma determined by inmunoperoxidase techniques (magnification, x400).
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Figure 3. Notch protein expression of (A) MCF‑10F; (B) Alpha5; (C) Tumor2 cell lines. Biopsy specimens containing (D) ductal carcinoma and (E and
F) invasive ductal carcinoma determined by immunoperoxidase technique (magnification, x400).
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Vimentin protein expression in breast cancer model and
breast biopsy specimens. Representative images of vimentin
protein expression, in which greater expression was observed
in the Alpha5 and Tumor2 cell lines compared with that in
the control MCF‑10F cell line, can be observed in immunoperoxidase (Fig. 2A‑C) and immunofluorescence (Fig. 2D‑F)
studies. Biopsy specimens were also analyzed for vimentin
protein expression to analyze progression in breast cancer.
Fig. 2G‑I shows representative tissues of vimentin protein
expression in ducts found in sections of biopsies from breast
cancer patients, as determined by immunoperoxidase staining.
This expression was negative in noninvasive ductal carcinoma
and breast epithelial lesions surrounding the primary tumors,
ductal and lobular hyperplasia, and microcytes. By contrast,
this expression was positive in breast specimens with invasive
characteristics, as shown in Fig. 2J‑L. Positive staining for
vimentin was found in 21% of cases.
Notch protein expression in breast cancer model and breast
biopsy specimens. In the present study, non‑malignant and
malignant cell lines from the model were used to analyze Notch
protein expression. Fig. 3A‑C shows higher Notch protein
expression in the Alpha5 and Tumor2 cell lines compared
with that in the control MCF‑10F cell line, as determined by
immunoperoxidase staining. Samples from biopsy specimens
showed negative Notch protein expression in noninvasive
ductal carcinomas. However, positive cell expression was
observed in those tissues with cells from invasive ductal
carcinomas (Fig. 3D‑F), particularly in invasive isolated tumor
cells. Positive staining for Notch was found in 25% of cases.
Discussion
The main purpose of the present study was to assess the prognostic value of the markers vimentin and Notch. Identification
of factors involved in cell proliferation and transformation
has been facilitated by studies using various human epithelial
cell lines. The analysis of immunoperoxidase and immunofluorescence data obtained in relation to the relative vimentin
expression indicated that such expression was significantly
greater in Tumor2 and Alpha5 when compared with MCF‑10F,
Estrogen and Alpha3 cell lines.
Results of pairwise comparisons of vimentin gene
expression in the different cell lines indicated that there
was no alteration in vimentin gene expression between
the MCF‑10F and Estrogen cell lines, while there was an
almost nine‑ and five‑fold alteration in the MCF‑10F/Alpha3
and Estrogen/Alpha5 combinations, respectively. There
were six‑ and four‑fold changes in gene expression between
Alpha5 and Tumor2, and Alpha3 and Tumor2, respectively.
Results of the same pairs of cell lines analyzed for Notch gene
expression indicated that there was no alteration between the
MCF‑10F and Estrogen, Estrogen and Alpha5, and Alpha3
and Alpha5 cell lines. By contrast, there was an almost
ten‑ and fourteen‑ fold alteration in the Alpha5/Tumor2 and
Alpha3/Tumor2 combinations, respectively, with higher
expression in Alpha3 and Alpha5 than in Tumor2 cells.
Vimentin protein expression in ducts in sections of biopsies
from breast cancer patients was found to be negative for
noninvasive ductal carcinoma, but positive for ductal carci-
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noma with invasive characteristics. Vimentin‑reactive cells
in benign and malignant breast tissue have been described in
many studies (26‑29). These studies reported that vimentin
expression appeared to be associated with poor prognosis in
node‑negative ductal breast carcinomas, and that vimentin was
preferentially expressed in human breast carcinomas with low
levels of estrogen receptors. Gene expression patterns of breast
carcinomas distinguished tumor subclasses with clinical
implications (30). A possible association was found between
the clinically aggressive behavior of tumors (28,29) and
estrogen receptor negativity (31,32), high Ki‑67 levels (32) and
poor differentiation of tumors with high‑grade and positive
vimentin protein expression. Domagala et al (29) reported that
vimentin was preferentially expressed in high‑grade ductal
and medullary, but not in lobular, breast carcinomas. Other
data showed that more invasive breast cancer lines expressed
vimentin, indicating its usefulness in identifying cases with
poorer prognosis (28,29).
Vimentin is known to be selectively expressed in aggressive
breast cancer cell lines (9). Elevated vimentin expression levels
correlate well with upregulated migration and invasion of
cancer cells (9,26). Sommers et al (27) showed that transfection
of noninvasive human breast cancer cell lines, such as MCF7,
with the vimentin gene led to accelerated invasiveness. The
authors also reported vimentin rather than keratin expression
in certain hormone‑independent breast cancer cell lines, and in
oncogene‑transformed mammary epithelial cells. The possible
association of vimentin with the clinically aggressive behavior
of tumors described by others (7,28‑32) may be explained by
the correlation of vimentin expression with a lack of steroid
receptors and poor differentiation of cancer. Gilles et al (31)
also found vimentin expression in cervical carcinomas was
associated with invasive and migratory potential.
Thus, we can suggest an improved indicator of breast
cancer progression by adding vimentin to the diagnostic panel
when overall survival is a primary end‑point. In the present
study, positive staining for vimentin was found in 21% of
cases, which is in line with previous findings (32). Therefore,
vimentin expression appears to predict survival in ductal
breast carcinoma.
Notch protein expression was also higher in the Alpha5
and Tumor2 cell lines in comparison with that in the control
MCF‑10F cell line. When samples from biopsy specimens were
analyzed for Notch protein expression, negative cells were found
in noninvasive ductal carcinomas while positive cells were found
in invasive ductal carcinomas. It has been reported that the
Notch pathway is required for the establishment of embryonic
hematopoietic stem cells (33), and it has been implicated in the
maintenance of several types of normal cell populations (34‑36).
The effects of Notch on cells include increased survival or death,
proliferation or growth arrest and commitment to, or blockage
of, differentiation. These different outcomes are mediated
through a novel signaling pathway in which Notch receptors on
the cell surface give rise to a nuclear transcriptional activation
complex. Studies on Notch are related to the understanding of
how this pathway yields several outcomes. It has been proposed
that Notch may serve as an oncogene or tumor suppressor, a
repressor or inducer of terminal differentiation, or a cancer stem
cell factor. Studies on the multifaceted role of Notch in cancer
indicate a possible therapeutic implication. Notch signaling is
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frequently deregulated in breast cancer, and hyperactivation of
Notch contributes to the tumor process. Notch has been shown
to be involved in the controlled proliferation and migration of
vascular endothelial cells, as well as in the integration of Notch
and Wnt signaling, as observed in hematopoietic stem cell
maintenance (34). Guentchev and McKay (35) observed that
Notch controlled the proliferation and differentiation of stem
cells in a dose‑dependent manner. It has also been suggested
that Notch acts as a transducer molecule for developmental
processes. Stylianou et al (36) observed aberrant activation of
Notch signaling in human breast cancer.
Estrogens are known to regulate the proliferation of breast
cancer cells and to alter their phenotypic properties; the gene
networks and pathways through which estrogenic hormones regulate these events have also been considered (37). We used global
gene expression profiling by Affymetrix GeneChip microarray
analysis to identify genes altered by the presence of estradiol in
an MCF‑10F human breast cancer model. Of the >14,000 genes
analyzed, over 300 showed a pattern of either up‑ or downregulation. We observed a general upregulation of positive proliferation
regulators, including multiple growth factors, genes involved in
cell cycle progression and regulatory factor‑receptor loops, and
a downregulation of transcriptional repressors and anti‑proliferative and pro‑apoptotic genes, including BCL2 and TGF‑β
family growth inhibitory factors. The present study highlights
the diverse gene networks and metabolic and cell regulatory
pathways through which this hormone operates to achieve its
widespread effects on breast cancer cells.
It can be concluded that vimentin and Notch gene and
protein expression are altered in breast cancer progression,
thereby helping to identify cases of breast cancer with poor
prognosis and complementing those biomarkers required for
assessing the prognosis of breast cancer patients.
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